semaglutide patent expiry india India's to boost affordable access | Ms. Priyanka S. posted on the topic Ozempic's India entry starts at

Eli Lilly plans to submit the daily orforglipron pill for global regulatory approval by the end of 2025, joining competitor Novo Nordisk, which is also seeking approval for an oral version of its Wegovy semaglutide medication

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Ozempic, Rybelsus) and chronic weight management (Wegovy)

GLP-1 Agonist Complications

Edaravone reduced downstream pathologies including tau hyperphosphorylation, glial activation, neuroinflammation, neuronal loss, and synaptic dysfunction

And the reason for that is several fold